Clinical trials: Retinopathy
Neovascular Age-related Macular Degeneration
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept injections in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD).
- Trial name
- PHTHALO-205 (NCT04331730)
- Testing
- AKST4290, Aflibercept
- Where
- 21 sites in United States, Germany and 2 more
- Volunteers
- 107 people
- Sponsor
- Alkahest, Inc.
Diabetes Mellitus, Type 2
Evaluation of Macular Structural and Functional Function Following Extensive Retinal Laser Therapy in Patients With Proliferative Diabetic Retinopathy
The present study is a semi-experimental clinical trial that 20 patients (40 eyes) with PDR underwent PRP with ARC with a spot number of 1,200 to 1,500 per eye and spot size 500 micron with a duration of 200 ms.
- Trial name
- NCT04436900
- Testing
- Panretinal Photocoagulation (PRP)
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Baqiyatallah Medical Sciences University
Age Related Macular Degeneration
A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal CNV Associated With Wet AMD in Patients That Require Persistent Anti-VEGF Therapy
The objective of the MERITAGE Trial is to evaluate the safety and efficacy of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) associated with wet age-related macular degeneration…
- Trial name
- MERITAGE (NCT00809419)
- Testing
- NeoVista Ophthalmic System
- Where
- 5 sites in United States, Israel and 1 more
- Volunteers
- 32 people
- Sponsor
- NeoVista
Age-Related Macular Degeneration
Alpha Lipoic Acid in Geographic Atrophy
Because of its iron-chelating and antioxidant properties, alpha lipoic acid may be a treatment for geographic atrophy (GA) secondary to age-related macular degeneration.
- Trial name
- ALA (NCT02613572)
- Testing
- alpha lipoic acid
- Where
- 5 sites in United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Dry Eye Syndromes, Age-Related Macular Degeneration
Preventive TREatment of Dry Eye in Patients Receiving Repeated Intravitreal Injections for Age-related Macular Degeneration
Age-related macular degeneration (AMD) is the 1st cause of visual impairment after the age of 50. Its most aggressive form, wet AMD, requires regular intravitreal injections (IVI) spaced 4 to 8 weeks apart usually depending on…
- Trial name
- TREDIA (NCT06174181)
- Testing
- Preservative-free ophtalmic lubricant emulsion, Routine treatment
- Where
- 2 sites in France
- Volunteers
- 42 people
- Sponsor
- Direction Centrale du Service de Santé des Armées
Macular Edema, Cystoid, Vision Disorders
Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema
This study is undertaken to determine the effect of intravitreal long acting dexamethasone implant, (Ozurdex®) in improving outcome of cataract surgery in patients with diabetic macular edema.
- Conditions
- Macular Edema, Cystoid, Vision Disorders, Diabetic Macular Edema, Cystoid Macular Edema Following Cataract Surgery
- Trial name
- NCT01546402
- Testing
- Dexamethasone Drug delivery system (Ozurdex), Cataract surgery
- Where
- India
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Macular Oedema, Cataract Surgery
Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery
The goal of this clinical trial is to learn which of the drugs bromfenac 0.09%, nepafenac 0.3% and diclofenac 0.1% has better efficacy in treatment and prevention of cystoid macular oedema after cataract surgery.
- Conditions
- Macular Oedema, Cataract Surgery, NSAID (Non-Steroidal Anti-Inflammatory Drug)
- Trial name
- BND (NCT07178639)
- Testing
- Bromfenac 0.09 % Ophthalmic Solution, Nepafenac 0.3% Oph Susp, diclofenac 0.1% ophthalmic susp.
- Where
- Czechia
- Volunteers
- 150 people
- Sponsor
- Nemocnice Kolín
Age-Related Macular Degeneration
Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
VAN-2201 is Phase I clinical trial to assess the safety and tolerability of KH631 in subjects with neovascular AMD. KH631 is gene therapy designed to deliver a protein which targets and blocks VEGF via an adeno-associated viral…
- Trial name
- NCT05657301
- Testing
- KH631
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
Age-related Macular Degeneration, Choroidal Neovascularization
Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
This study was designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration
- Trial name
- TREND (NCT01948830)
- Testing
- Ranibizumab 0.5mg
- Where
- 91 sites in Belgium, Chile and 17 more
- Volunteers
- 650 people
- Sponsor
- Novartis Pharmaceuticals
Retinoblastoma
Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma
The purpose of this study is to show that chemotherapy delivered directly through the artery supplying the eye (ophthalmic artery) to patients with retinoblastoma is a safe and effective treatment alternative to conventional…
- Trial name
- NCT01293539
- Testing
- Melphalan hydrochloride
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Retinal Detachment
Subconjunctiva Bupivacaine as Analgesia in Intravitreal Silicone Oil Removal
The study aimed to investigate the effectivity of bupivacaine 0,5% as post-operative analgesia in intravitreal silicone evacutaion surgery
- Trial name
- NCT03046719
- Testing
- Bupivacaine 0,5%, NaCl 0,9%
- Where
- Indonesia
- Volunteers
- 30 people
- Sponsor
- Universitas Indonesia
Age Related Macular Degeneration
French Evaluation Group Avastin Versus Lucentis
Age Related Macular Degeneration (AMD) is the first cause of visual impairment in elderly patients in industrialized countries. Neovascular or "wet" AMD, characterized by the presence of choroïdal neovessels, represents the most…
- Trial name
- GEFAL (NCT01170767)
- Testing
- Avastin, Lucentis
- Where
- France
- Volunteers
- 501 people
- Sponsor
- Hospices Civils de Lyon
Macular Degeneration
Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD
To assess genetic features and intraocular cytokine profiles of non-responders to anti-VEGF treatment of exudative age-related macular degeneration. Also to assess necessity and frequency of pro re nate medical re-treatment.
- Trial name
- RESPONSE (NCT01213667)
- Testing
- Ranibizumab
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- University of Cologne
AMD, Exudative Macular Degeneration
CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)
The main objective of this study is to analyze a new noninvasive imaging examination, OCT angiography, in the evaluation of neovascular remodeling and early signs of recurrence of wet AMD undergoing treatment on OCTA and to…
- Trial name
- COCTAEyl (NCT03803631)
- Where
- 5 sites in France
- Volunteers
- 49 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD)
Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention
The study will explore the impact of photobiomodulation (PBM), pulsating at frequencies of red (660nm) and near-infrared (810nm)(NIR), concurrent with a ketogenic dietary protocol (serum ketones @ .5 - 2.0 mmol/L) to mediate…
- Conditions
- Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
- Trial name
- NCT03859245
- Testing
- Photobiomodulation, Ketogenic diet
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristlecone Health, Inc.
Macular Edema
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
The Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator is used to deliver an implant with medicine to the eye. AbbVie is updating the DEX PS DDS Applicator.
- Trial name
- NCT04976777
- Testing
- Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- AbbVie
Choroidal Neovascularization, Age-Related Macular Degeneration
Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)
Randomized controlled clinical trial of periocular corticosteroids as adjunctive therapy to photodynamic therapy (PDT) for patients with neovascular age-related macular degeneration (AMD).
- Trial name
- NCT00305630
- Testing
- Periocular injection of triamcinolone acetonide 40mg
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Johns Hopkins University
Macular Degeneration
Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)
Stage 1 is a patient-masked, dose-escalation, safety evaluation of brimonidine intravitreal implant. Patients will receive implant in one eye and "sham" treatment (meaning no treatment) in the fellow eye.
- Trial name
- NCT00658619
- Testing
- 400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 119 people
- Sponsor
- Allergan
Central Serous Chorioretinopathy
Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC)
The purpose of this study is to determine the safety and efficacy of PDT at 30% verteporfin dose in the treatment of CSC.
- Trial name
- NCT01574430
- Testing
- PDT
- Where
- China
- Volunteers
- 131 people
- Sponsor
- Peking University People's Hospital
Retinitis Pigmentosa
Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa
This project intends to transplant a clinical level human embryonic stem cells derived retinal pigment epithelium into subretinal space to treat eetinitis pigmentosa(RP) diseases.
- Trial name
- NCT03944239
- Testing
- Retinal pigment epitheliums transplantation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Qi Zhou